Astellas and Gilead In Spotlight As Compulsory Licensing Pressure Mounts In Chile
Executive Summary
Pressure is mounting in Chile for the government to pursue compulsory licensing. Gilead’s Sovadi (sofosbuvir) and Astellas’s prostate cancer drug Xtandi (enzalutamide) could be among the drugs eventually opened up to generic competition.